极薄支架生物可降解聚合物依维莫司与西罗莫司洗脱支架对比 durable 聚合物佐他莫司洗脱支架在冠心病全人群中的研究(BIO-RESORT):三臂随机非劣效试验
BIO-RESORT为研究者发起的多中心、评估者与患者盲法、三臂随机非劣效试验,在荷兰4个临床中心纳入3514例18岁以上需经皮冠状动脉介入治疗并植入药物洗脱支架的全人群患者,按1:1:1随机分配至极薄支架生物可降解聚合物依维莫司洗脱支架组(1172例)、西罗莫司洗脱支架组(1169例)或薄支架 durable 聚合物佐他莫司洗脱支架组(1173例)。主要终点为12个月随访时安全(心源性死亡或靶血管相关心肌梗死)与 efficacy(靶血管血运重建)的复合终点,非劣效界值3.5%。结果显示依维莫司组55例(5%)、西罗莫司组55例(5%)、佐他莫司组63例(5%)达到主要终点,两种生物可降解聚合物支架对比佐他莫司支架的绝对风险差均为-0.7%(95%CI -2.4至1.1;单侧95%CI上限0.8%,p非劣效<0.0001),非劣效性成立。确定的支架血栓(学术研究联合会定义)在三组分别为4例(0.3%)、4例(0.3%)、3例(0.3%)(与佐他莫司支架比较的log-rank p=0.70)。作者认为,在12个月随访时,两种极薄支架生物可降解聚合物涂层药物洗脱支架(分别洗脱依维莫司或西罗莫司)在治疗全人群冠心病(急性冠脉综合征比例高)中非劣于 durable 聚合物佐他莫司洗脱支架;在评估其潜在长期获益之前,这两种生物可降解聚合物涂层支架未出现1年安全性和疗效损失是前提条件。
要点
- 在3514例全人群冠心病患者(2449例[70%]为急性冠脉综合征,其中1073例[31%]为ST段抬高型心肌梗死)中,12个月主要终点发生率依维莫司组5%、西罗莫司组5%、佐他莫司组5%。
- 两种极薄支架生物可降解聚合物支架对比 durable 聚合物佐他莫司支架的绝对风险差均为-0.7%(95%CI -2.4至1.1),单侧95%CI上限0.8%,低于预设非劣效界值3.5%,非劣效性成立(p非劣效<0.0001)。
- 确定的支架血栓(学术研究联合会定义)发生率依维莫司组0.3%、西罗莫司组0.3%、佐他莫司组0.3%,与佐他莫司支架比较的log-rank p=0.70。
- 作者认为,在评估两种生物可降解聚合物涂层支架的潜在长期获益之前,其1年安全性和疗效未出现损失是前提条件。
适用人群与场景
- 全人群(all-comers)患者,年龄18岁或以上,能够提供知情同意,根据临床指南或术者判断需经皮冠状动脉介入治疗并植入药物洗脱支架。
- 排除标准:在达到另一项随机药物或器械研究的主要终点前参与该研究;计划6个月内需中断双联抗血小板治疗的手术;已知对研究产品成分或所需药物不耐受;对随访程序依从性不确定或预期寿命不足1年;已知妊娠。
- 纳入患者中2449例(70%)为急性冠脉综合征,包括1073例(31%)ST段抬高型心肌梗死。
诊断标准与关键阈值
- 主要终点为12个月随访时安全(心源性死亡或靶血管相关心肌梗死)与疗效(靶血管血运重建)的复合终点。
- 非劣效界值为3.5%。
- 确定的支架血栓采用学术研究联合会(Academic Research Consortium)定义。
研究设计与关键结果
- 研究类型:大规模、研究者发起的多中心、评估者与患者盲法、三臂、随机、非劣效试验(BIO-RESORT),在荷兰4个临床中心进行。
- 样本量:从2012年12月21日至2015年8月24日共纳入并分析3514例患者,随机分配至依维莫司洗脱支架组1172例、西罗莫司洗脱支架组1169例、佐他莫司洗脱支架组1173例(1:1:1)。
- 主要终点:12个月随访时依维莫司组55例(5%)、西罗莫司组55例(5%)、佐他莫司组63例(5%)达到主要终点;两种生物可降解聚合物支架对比佐他莫司支架的绝对风险差均为-0.7%(95%CI -2.4至1.1),单侧95%CI上限0.8%,p非劣效<0.0001。
- 关键次要终点:确定的支架血栓依维莫司组4例(0.3%)、西罗莫司组4例(0.3%)、佐他莫司组3例(0.3%),与佐他莫司支架比较的log-rank p=0.70。
- 随访:12个月随访获得3490例(99%)患者的数据(失访3例,退出21例)。
证据类型、等级与局限
- 证据类型:三臂随机非劣效试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在12个月随访时,两种极薄支架生物可降解聚合物涂层药物洗脱支架(分别洗脱依维莫司或西罗莫司)在治疗全人群冠心病(急性冠脉综合征比例高)中非劣于 durable 聚合物佐他莫司洗脱支架。
- 作者认为,在评估这两种生物可降解聚合物涂层支架的潜在长期获益之前,其1年安全性和疗效未出现损失是前提条件。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients with coronary artery disease, treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer might delay arterial healing. Novel very thin strut biodegradable polymer stents, which leave only a bare metal stent after polymer resorption, might improve long-term outcome. We investigated in allcomers the safety and efficacy of three stents eluting either everolimus, sirolimus, or zotarolimus, often clinically used but never compared, of which the biodegradable polymer everolimus-eluting stent was never before assessed in allcomers.
METHODS: The large-scale, investigator-initiated, multicentre, assessor and patient blinded, three-arm, randomised, BIO-RESORT non-inferiority trial was done at four clinical sites in the Netherlands. All-comer patients were aged 18 years or older, capable of providing informed consent, and required a percutaneous coronary intervention with drug-eluting stent implantation according to clinical guidelines or the operators' judgment. Exclusion criteria were: participation in another randomised drug or device study before reaching the primary endpoint of that study; planned surgery necessitating interruption of dual antiplatelet therapy within the first 6 months; known intolerance to components of the investigational product or medication required; uncertainty about the adherence to follow-up procedures or an assumed life expectancy of less than 1 year; or known pregnancy. Web-based computer-generated allocation sequences randomly assigned patients (1:1:1) to treatment with very thin strut biodegradable polymer everolimus-eluting or sirolimus-eluting stents (which differ substantially in type, amount, distribution, and resorption speed of their respective coating), or thin strut durable polymer zotarolimus-eluting stents. The primary endpoint was a composite of safety (cardiac death or target vessel-related myocardial infarction) and efficacy (target vessel revascularisation) at 12 months of follow up with a very thin strut biodegradable polymer of either everolimus-eluting or sirolimus-eluting stents, compared with durable polymer zotarolimus-eluting stents, analysed by intention to treat (non-inferiority margin 3·5%). This trial was registered with ClinicalTrials.gov, number NCT01674803.
FINDINGS: From Dec 21, 2012, to Aug 24, 2015, 3514 patients were enrolled and analysed, of whom 2449 (70%) had acute coronary syndromes, which included 1073 (31%) ST-elevation myocardial infarctions. 12 month follow-up of 3490 (99%) patients (three lost to follow-up; 21 withdrawals) was available. The primary endpoint was met by 55 (5%) of 1172 patients assigned to everolimus-eluting stents, 55 (5%) of 1169 assigned to sirolimus-eluting stents and 63 (5%) of 1173 assigned to zotarolimus-eluting stents. Non-inferiority of the everolimus-eluting stents and sirolimus-eluting stents compared with zotarolimus-eluting stents was confirmed (both -0·7% absolute risk difference, 95% CI -2·4 to 1·1; upper limit of one sided 95% CI 0·8%, pnon-inferiority<0·0001). Definite stent thrombosis (defined by the Academic Research Consortium) occurred in four (0·3%) of 1172 patients who were allocated to everolimus-eluting stents, four (0·3%) of 1169 patients who were allocated to sirolimus-eluting stents, and three (0·3%) of 1173 patients who were allocated to zotarolimus-eluting stents (log-rank p=0·70 for both comparisons with zotarolimus-eluting stents).
INTERPRETATION: At 12 month follow-up, both very thin strut drug-eluting stents with dissimilar biodegradable polymer coatings (eluting either everolimus or sirolimus) were non-inferior to the durable polymer stent (eluting zotarolimus) in treating allcomers with a high proportion of patients with acute coronary syndromes. The absence of a loss of 1 year safety and efficacy with the use of these two biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits.
FUNDING: Biotronik, Boston Scientific, and Medtronic.
参考来源
- von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016. PMID: 27806902. doi:10.1016/S0140-6736(16)31920-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。